A dual macrophage polarizer conjugate for synergistic melanoma therapy.

[1]  S. Mitragotri,et al.  Hyaluronic Acid Conjugates of Vorinostat and Bexarotene for Treatment of Cutaneous Malignancies , 2020 .

[2]  S. Mitragotri,et al.  Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function , 2020, Proceedings of the National Academy of Sciences.

[3]  M. Sokolsky-Papkov,et al.  High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. , 2020, Science advances.

[4]  S. Mitragotri,et al.  Cellular backpacks for macrophage immunotherapy , 2020, Science Advances.

[5]  J. Carucci,et al.  Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer , 2020, Facial Plastic Surgery.

[6]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[7]  Yichao Chen,et al.  High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy , 2020, Theranostics.

[8]  S. Mitragotri,et al.  Macrophage‐Mediated Delivery of Hypoxia‐Activated Prodrug Nanoparticles , 2019, Advanced Therapeutics.

[9]  L. Sansing,et al.  Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage , 2019, Stroke.

[10]  S. Mitragotri,et al.  Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. , 2019, Advanced drug delivery reviews.

[11]  R. Carvajal,et al.  Novel Targets for the Treatment of Melanoma , 2019, Current Oncology Reports.

[12]  A. Kulkarni,et al.  CSF1R‐ and SHP2‐Inhibitor‐Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor‐Associated Macrophages , 2019, Advanced materials.

[13]  S. Fukushima,et al.  Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma , 2019, Front. Oncol..

[14]  S. Walmsley,et al.  Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. , 2019, Trends in molecular medicine.

[15]  D. Ford,et al.  TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy. , 2019, Cell metabolism.

[16]  Kimberly R. Jordan,et al.  Targeting myeloid‐derived suppressor cells using all‐trans retinoic acid in melanoma patients treated with Ipilimumab , 2018, International immunopharmacology.

[17]  Shiladitya Sengupta,et al.  A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer , 2018, Nature Biomedical Engineering.

[18]  Michael F. Cuccarese,et al.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.

[19]  Xian Wang,et al.  HIF1α-Induced Glycolysis Metabolism Is Essential to the Activation of Inflammatory Macrophages , 2017, Mediators of inflammation.

[20]  S. Mitragotri,et al.  A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[21]  P. Allavena,et al.  Targeting tumor associated macrophages: The new challenge for nanomedicine. , 2017, Seminars in immunology.

[22]  Q. Luo,et al.  Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. , 2017, ACS nano.

[23]  S. Mitragotri,et al.  A review on engineering polymer drug conjugates to improve combination chemotherapy , 2017 .

[24]  Ou Sha,et al.  Anti-tumor Activity of Toll-Like Receptor 7 Agonists , 2017, Front. Pharmacol..

[25]  A. Letai,et al.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.

[26]  Ralph Weissleder,et al.  Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging , 2017, Nature Communications.

[27]  I. Stratford,et al.  The CD44‐Mediated Uptake of Hyaluronic Acid‐Based Carriers in Macrophages , 2017, Advanced healthcare materials.

[28]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[29]  S. Mehrotra,et al.  Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. , 2016, Cancer research.

[30]  Yukio Fujiwara,et al.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.

[31]  Li Li,et al.  Preparation, in vitro and in vivo evaluation of bexarotene nanocrystals with surface modification by folate-chitosan conjugates , 2016, Drug delivery.

[32]  M. Amiji,et al.  Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles , 2015, Scientific Reports.

[33]  Shiyin Yao,et al.  Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. , 2015, Bioconjugate chemistry.

[34]  Ram I Mahato,et al.  Nanoparticle-mediated drug delivery for treating melanoma. , 2015, Nanomedicine.

[35]  S. Mitragotri,et al.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[36]  H. Byrne,et al.  Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells , 2015, Advanced functional materials.

[37]  Jean Felix Mukerabigwi,et al.  Precise Ratiometric Control of Dual Drugs through a Single Macromolecule for Combination Therapy. , 2015, Molecular pharmaceutics.

[38]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[39]  P. Allavena,et al.  The interaction of anticancer therapies with tumor-associated macrophages , 2015, The Journal of experimental medicine.

[40]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[41]  P. Murray,et al.  Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer , 2015, Nature Medicine.

[42]  R. Satchi‐Fainaro,et al.  Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[43]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[44]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[45]  Thomas A. Wynn,et al.  Macrophage biology in development, homeostasis and disease , 2013, Nature.

[46]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[47]  C. Hotz,et al.  Systemic cancer immunotherapy with Toll-like receptor 7 agonists , 2012, Oncoimmunology.

[48]  C. Hotz,et al.  Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. , 2011, Cancer research.

[49]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[50]  Hailing Lu,et al.  The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system , 2011, Expert review of clinical pharmacology.

[51]  K. Ulbrich,et al.  Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.

[52]  Z. Berneman,et al.  The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. , 2008, The oncologist.

[53]  V. Singh,et al.  The role of nitric oxide in inflammatory reactions. , 2007, FEMS immunology and medical microbiology.

[54]  M. Fishman,et al.  Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. , 2007, Cancer research.

[55]  P. Nowell,et al.  Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene , 2007, Cancer biology & therapy.

[56]  R. Foà,et al.  The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. , 2003, Cancer research.

[57]  D. Irvine,et al.  Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. , 2019, Biomaterials.

[58]  Yao-Xin Lin,et al.  Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. , 2017, Biomaterials.